News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
145,283 Results
Type
Article (7937)
Company Profile (34)
Press Release (137312)
Multimedia
Podcasts (3)
Webinars (2)
Section
Business (43493)
Career Advice (239)
Deals (5205)
Drug Delivery (15)
Drug Development (21236)
Employer Resources (35)
FDA (2589)
Job Trends (3622)
News (72013)
Policy (5211)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (2)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (2)
2024 Genetown Standard (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 Pharm Country Standard (1)
Academia (915)
Accelerated approval (1)
Adcomms (3)
Allergies (23)
Alliances (12048)
ALS (30)
Alzheimer's disease (550)
Antibody-drug conjugate (ADC) (27)
Approvals (2594)
Artificial intelligence (76)
Autoimmune disease (5)
Automation (5)
Bankruptcy (31)
Best Places to Work (3199)
BIOSECURE Act (1)
Biosimilars (19)
Biotechnology (23)
Bladder cancer (27)
Brain cancer (8)
Breast cancer (99)
Cancer (659)
Cardiovascular disease (73)
Career advice (223)
Career pathing (8)
CAR-T (43)
Cell therapy (113)
Cervical cancer (2)
Clinical research (16612)
Collaboration (240)
Compensation (33)
Complete response letters (3)
COVID-19 (702)
CRISPR (18)
C-suite (100)
Cystic fibrosis (37)
Data (798)
Denatured (1)
Depression (12)
Diabetes (67)
Diagnostics (1550)
Digital health (2)
Diversity, equity & inclusion (9)
Drug discovery (36)
Drug pricing (9)
Drug shortages (3)
Duchenne muscular dystrophy (34)
Earnings (11109)
Editorial (8)
Employer branding (7)
Employer resources (33)
Events (22620)
Executive appointments (246)
FDA (2872)
Featured Employer (13)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (240)
Gene editing (38)
Generative AI (8)
Gene therapy (85)
GLP-1 (175)
Government (917)
Guidances (13)
Healthcare (3873)
Huntington's disease (3)
IgA nephropathy (6)
Immunology and inflammation (23)
Indications (9)
Infectious disease (737)
Inflammatory bowel disease (46)
Influenza (11)
Intellectual property (23)
Interviews (34)
IPO (2037)
IRA (5)
Job creations (623)
Job search strategy (201)
Kidney cancer (2)
Labor market (7)
Layoffs (89)
Leadership (5)
Legal (881)
Liver cancer (15)
Lung cancer (84)
Lymphoma (39)
Machine learning (4)
Management (11)
Manufacturing (54)
MASH (23)
Medical device (1799)
Medtech (1801)
Mergers & acquisitions (3290)
Metabolic disorders (176)
Multiple sclerosis (22)
NASH (5)
Neurodegenerative disease (30)
Neuropsychiatric disorders (8)
Neuroscience (719)
NextGen: Class of 2025 (1273)
Non-profit (1398)
Northern California (639)
Now hiring (6)
Obesity (87)
Opinion (49)
Ovarian cancer (13)
Pain (18)
Pancreatic cancer (18)
Parkinson's disease (54)
Partnered (5)
Patents (45)
Patient recruitment (28)
Peanut (9)
People (18118)
Pharmaceutical (7)
Phase I (4959)
Phase II (7025)
Phase III (5814)
Pipeline (320)
Policy (24)
Postmarket research (663)
Preclinical (3228)
Press Release (33)
Prostate cancer (31)
Psychedelics (11)
Radiopharmaceuticals (48)
Rare diseases (112)
Real estate (1217)
Recruiting (15)
Regulatory (3904)
Reports (8)
Research institute (1025)
Resumes & cover letters (23)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (18)
Series A (60)
Series B (18)
Sickle cell disease (24)
Southern California (518)
Special edition (1)
Spinal muscular atrophy (66)
Sponsored (14)
Startups (1182)
State (1)
Stomach cancer (3)
Supply chain (9)
Tariffs (2)
The Weekly (2)
United States (5708)
Vaccines (139)
Venture capitalists (8)
Weight loss (37)
Women's health (7)
Worklife (2)
Date
Today (24)
Last 7 days (235)
Last 30 days (730)
Last 365 days (8304)
2025 (2627)
2024 (8870)
2023 (10134)
2022 (12901)
2021 (14122)
2020 (12487)
2019 (10036)
2018 (7698)
2017 (7858)
2016 (7576)
2015 (8162)
2014 (5961)
2013 (4756)
2012 (4881)
2011 (5147)
2010 (4329)
Location
Africa (162)
Alabama (12)
Alaska (4)
Arizona (32)
Arkansas (2)
Asia (7972)
Australia (1353)
California (1412)
Canada (526)
China (106)
Colorado (72)
Connecticut (72)
Delaware (35)
Europe (22055)
Florida (162)
Georgia (49)
Idaho (9)
Illinois (101)
India (2)
Indiana (54)
Iowa (2)
Japan (39)
Kansas (11)
Kentucky (4)
Louisiana (3)
Maine (38)
Maryland (178)
Massachusetts (1293)
Michigan (75)
Minnesota (61)
Missouri (21)
Montana (5)
Nebraska (6)
Nevada (14)
New Hampshire (14)
New Jersey (398)
New Mexico (21)
New York (523)
North Carolina (220)
North Dakota (2)
Northern California (639)
Ohio (68)
Oklahoma (6)
Oregon (19)
Pennsylvania (341)
Puerto Rico (2)
Rhode Island (14)
South America (196)
South Carolina (3)
Southern California (518)
Tennessee (19)
Texas (239)
Utah (68)
Virginia (32)
Washington D.C. (8)
Washington State (142)
Wisconsin (13)
145,283 Results for "elixirgen scientific".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
Elixirgen Scientific Achieves ISO 9001 QMS Certification
Baltimore-based biotechnology leader, Elixirgen Scientific, Inc., achieves ISO 9001:2015 Quality Management System certification, strengthening commitment to quality, excellence in biotechnology and drug discovery.
March 12, 2024
·
3 min read
Press Releases
Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders
February 21, 2025
·
2 min read
Press Releases
Elixirgen Therapeutics Publishes Early Results Showing Telomere Elongation in First Gene Therapy Trial for Telomere Biology Disorders
February 25, 2025
·
5 min read
Elixirgen Scientific, Inc. Achieves ISO 9001:2015 Certification, Strengthening Commitment to Quality, Excellence in Biotechnology
Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, announced today that it has been accredited for ISO 9001:2015 certification.
March 8, 2024
·
3 min read
Press Releases
Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EXG-34217 for Treatment of Telomere Biology Disorders
February 14, 2025
·
2 min read
BioCapital
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Elixirgen Therapeutics, Inc., today presented preclinical data on its proprietary Bobcat mRNA TM technology in a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 3-6, 2024, in Orlando, Florida.
March 4, 2024
·
2 min read
News
Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease
July 16, 2024
·
2 min read
Press Releases
Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders
September 26, 2024
·
2 min read
Drug Development
Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2
Elixirgen Therapeutics, Inc. today announced promising data from a Phase 1/2 trial (NCT04863131) evaluating EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology.
October 16, 2023
·
4 min read
BioCapital
Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference
Elixirgen Therapeutics, Inc. announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California.
January 4, 2023
·
1 min read
1 of 14,529
Next
